EN DE
Watch BioCryst Pharmaceuticals Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

BioCryst Pharmaceuticals Inc (BCRX) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of BioCryst Pharmaceuticals Inc stock $17.01, price $7.69, upside +121.2%, quality 72 out of 100. Rating: strongly undervalued. Calculated from audited financials with 21 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

BP BioCryst Pharmaceuticals Inc logo Thin data Nov 7, 2026

BioCryst Pharmaceuticals Inc

BCRX · US
Meets all rules

The stock costs 55% less than our calculation considers fair.

Fair value $17.01 · Strongly undervalued
Quality 72/100
Generates free cash flow
Ranks above peers (8/10)
Positive coverage
Even on cautious assumptions the value is 46% above the price ($11.26).
Mixed Growth (revenue 3y +47.8 %/yr in USD)
Loss over the last twelve months · -37.4% net margin (TTM) · fiscal year 2025 30.2%
Negative equity (buybacks among others)
Moderate moat 64/100 · thin data
Insiders sold $696,535 (6M)
Thin data
⚠ Dilution
Watch BioCryst Pharmaceuticals Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$19.76 $4.13 Fair Value $17.01 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 7, 2026.

How to read this chart

60‑month range $4.13 – $19.76 · fair‑value band $11.26 – $22.12 · the $7.69 price screens below the $17.01 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 7, 2026.

Follow BioCryst Pharmaceuticals in your weekly email

Every Wednesday you see whether BioCryst Pharmaceuticals is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases.

Show moreShow less

The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial.

The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Stock analysis

BioCryst Pharmaceuticals Inc (BCRX) currently trades at $7.69, while our model-based Fair Value estimate is $17.01, implying the stock looks roughly 55% undervalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of $20.01 per share, and 19 of the 21 models we run sit above the $7.69 price.

Bear case: the Earnings-Based group reads lowest at $8.86, and 2 of the 21 models stay below the price. Data coverage for this calculation is low.

Scenario range: $11.26 (bear) to $22.12 (bull), the price of $7.69 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 72/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

BioCryst Pharmaceuticals Inc reported revenue of $875M in FY2025 versus $157M in FY2021, a compound +53.6%/yr. Reported net income was $264M in FY2025.

Key figures

Market cap $2.0B Mid · P/S ratio 2.04 · EPS (TTM) $−1.28 · Net margin −37.4% · Return on equity −1,925% · Return on assets (EBIT) −2.3% (5-year average) · Operating margin 29.6% · Revenue (TTM) $962M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 64 out of 100 (low confidence).

What moves the price

The share trades about 31% below its 52-week high and 23% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 121%, BCRX screens cheaper than that median.

Fair Value models

Bear $11.26 Fair Value $17.01 Bull $22.12
Price $7.69 · Upside +121.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF $14.89 $23.17 $35.03 80
Growth DCF $15.07 $22.29 $32.00 78
Owner Earnings $9.95 $15.70 $23.94 76
All 21 models by family
DCF Models
FCF DCF $14.89 $23.17 $35.03 80
Owner Earnings $9.95 $15.70 $23.94 76
5Y Revenue Exit $8.97 $13.45 $18.95 73
5Y EBITDA Exit $12.51 $20.08 $28.82 75
5Y P/E Exit $14.16 $23.18 $32.61 70
10Y Revenue Exit $10.88 $15.41 $21.19 67
10Y EBITDA Exit $13.25 $19.85 $28.45 68
10Y P/E Exit $14.27 $21.93 $31.24 64
Earnings-Based
Graham-Dodd $6.97 $22.10 $29.44 64
Lynch FV $4.86 $6.94 $9.03 61
PEG = 1.0 $4.86 $6.94 $9.03 57
EPV $9.19 $10.78 $12.15 74
Multiples
P/E Multiple $16.92 $22.56 $28.20 63
P/S Multiple $8.93 $11.90 $14.88 58
EV/EBIT $15.39 $21.02 $26.66 66
EV/EBITDA $12.47 $17.12 $21.78 67
EV/Revenue $5.63 $8.69 $11.75 53
Growth DCF
Growth DCF $15.07 $22.29 $32.00 78
Rev-Margin DCF $8.97 $13.64 $19.11 73
Economic Profit
ROIC Compounder $9.39 $11.25 $12.99 72
Growth Earnings
Growth-Adj P/E $14.01 $20.01 $26.02 67

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 72/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 100
How much profit the company makes from its sales and capital
Quality Growth 91
Are margins and returns getting better?
Cashflow 88
Do the profits arrive as real cash?
Financial strength 45
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 63
How calm the share price moves, does not count
Price momentum 32
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 36
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 2 officers or directors sold shares worth $696,535 and none bought.

  • SaleAmy E McKeeDirector11,180 shares at $8.97$100,285May 18, 2026
  • SaleAlane P BarnesChief Legal Officer5× since Dec 1, 2025: 417,163 shares, avg. $8.30$3.5MMay 13, 202610b5-1 plan
  • SaleTheresa HeggieDirector49,933 shares at $10.11$504,823Mar 20, 2026
  • SaleMachelle SandersDirector9,600 shares at $7.14$68,544Nov 13, 202510b5-1 plan

Plus 20 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 6, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 82/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+94.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+47.8%
Revenue growth 31 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+25.9%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−981.1% (2020) → 39.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: no profitable base year
not computed

Growth Forecast

Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−9.7%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
−1.5%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about −11.8% a year for the price and −3.8% for the forecasts.
Forecast 2026 (sales)−18.8%
Forecast 2027 (sales)+3.7%
Projected 2028 (sales)+3.5%
Projected 2029 (sales)+3.3%
Projected 2030 (sales)+3.1%

Watch BCRX, get fair value alerts →

Recent news

News mood ⓘNews mood, the average tone of recent news (92 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Positive
Recent news coverage is more positive than average.

Compare BioCryst Pharmaceuticals Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks

Beats the industry median on 8/10 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 72 · Top 25%
Fair Value upside +121.2% · Top 25%
Profitability
Return on equity (12 months) Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets 51.3% · Top 25%
Net margin (12 months) −37.4% · Bottom 25%
Operating margin (12 months) 29.6% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) 13.1% · Above median
Balance sheet
Debt / equity Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (12 months) 2.12× · Cheaper than median
Price / free cash flow (fiscal year) 6.2× · Cheapest 25%
EV/EBITDA 5.7× · Cheapest 25%
PEG 9.39× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 15
FUTURE (revenue growth)66 · sector 25
PAST (return on equity)0 · sector 29
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 32

PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $79.40 $111.63 +41% vs BCRX
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥50.43 ¥55.21 +9% vs BCRX
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,860 ₹1,947 +5% vs BCRX
Haleon plc HLN $9.14 $8.61 −6% vs BCRX
Merck KGaA MRK €148.75 €109.18 −27% vs BCRX
Galderma Group GALD CHF 191.75 CHF 109.86 −43% vs BCRX
Takeda Pharmaceutical Company TAK $21.02 $11.31 −46% vs BCRX
Teva Pharmaceutical Industries Limited TEVA $42.61 $20.74 −51% vs BCRX
Sandoz Group SDZ CHF 83.78 CHF 39.70 −53% vs BCRX
Divi's Laboratories Limited DIVISLAB ₹10,321 ₹1,567 −85% vs BCRX

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

BioCryst Pharmaceuticals Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "BioCryst Pharmaceuticals Inc Fair Value". https://www.fairvalue-calculator.com/stock/BCRX

Frequently asked questions

Is BioCryst Pharmaceuticals Inc (BCRX) overvalued or undervalued?
As of Nov 7, 2026, our model estimates a fair value of $17.01 versus a price of $7.69, about +121% upside (undervalued).
What is the fair value of BCRX?
Our model-based fair value for BioCryst Pharmaceuticals Inc is $17.01 (as of Nov 7, 2026), built from audited fundamentals. The current price: $7.69.
What is the quality score of BCRX?
BioCryst Pharmaceuticals Inc has a Quality Score of 72/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for BioCryst Pharmaceuticals Inc (BCRX)?
Our model-based price target is the fair value of $17.01 (as of Nov 7, 2026) from 21 valuation models. Cautious scenario $11.26, optimistic scenario $22.12. It is a calculation from audited fundamentals, not an analyst target.
What is the BioCryst Pharmaceuticals Inc stock forecast for 2026?
Our models put fair value at $17.01, about +121% upside versus a price of $7.69 (undervalued). Cautious scenario $11.26, optimistic scenario $22.12. The calculation is refreshed regularly with new filings.
What is the revenue of BioCryst Pharmaceuticals Inc (BCRX)?
BioCryst Pharmaceuticals Inc reported trailing-twelve-month revenue of about $962M (latest available figure, as of Nov 7, 2026).
What growth is priced into BioCryst Pharmaceuticals Inc (BCRX)?
For today's price to be fair in a discounted-cash-flow model, BioCryst Pharmaceuticals Inc would have to grow free cash flow by -9.7 % per year for five years (discount rate 9.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +117.9 % per year. As of Nov 7, 2026.
What discount rate (WACC) does the fair value of BCRX use?
Our models discount BioCryst Pharmaceuticals Inc at 9.9 %: a base by market capitalisation (small), damped by beta 0.51, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For BioCryst Pharmaceuticals Inc that is -9.7 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.9 %) and the same formula as our fair value.
How much growth has BioCryst Pharmaceuticals Inc (BCRX) delivered so far?
Over the past 5 years revenue at BioCryst Pharmaceuticals Inc grew +117.9 % a year. The price currently implies free-cash-flow growth of -9.7 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of BioCryst Pharmaceuticals Inc (BCRX) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into BioCryst Pharmaceuticals Inc (-9.7 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of BioCryst Pharmaceuticals Inc (BCRX)?
The free-cash-flow yield on the price is 16.06 %: that much free cash flow BioCryst Pharmaceuticals Inc produces per unit of market value. When it exceeds the discount rate of our models (9.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of BioCryst Pharmaceuticals Inc (BCRX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For BioCryst Pharmaceuticals Inc it is $17.01 per share (as of Nov 7, 2026), against a price of $7.69. It is the blended result of 21 valuation models in 6 families (DCF Models, Earnings-Based, Multiples, Growth DCF, Economic Profit, Growth Earnings).
Is BioCryst Pharmaceuticals Inc stock overvalued or undervalued in 2026?
As of Nov 7, 2026, BCRX trades below its calculated fair value: price $7.69, fair value $17.01, a gap of about +121% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BCRX?
No. The price is what the market pays today ($7.69); the fair value is what the company's own numbers justify ($17.01). For BioCryst Pharmaceuticals Inc the two are $9.32 per share apart. That gap is exactly why we show both numbers side by side.
How much is BioCryst Pharmaceuticals Inc worth?
The market values BioCryst Pharmaceuticals Inc at about $2.0B (market capitalisation, as of Nov 7, 2026). Per share that is $7.69; our models calculate a fair value of $17.01 per share.
What do the bullish and bearish scenarios say about BCRX?
Our models span a range for BioCryst Pharmaceuticals Inc: cautious scenario $11.26, base $17.01, optimistic $22.12 per share (as of Nov 7, 2026, price $7.69). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of BCRX?
The PEG ratio of BioCryst Pharmaceuticals Inc is 9.39 (P/E divided by earnings growth, as of Nov 7, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of BioCryst Pharmaceuticals Inc (BCRX)?
Balance-sheet figures for BioCryst Pharmaceuticals Inc (as of Nov 7, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 72/100, which measures business quality independently of the share price.
How far is BCRX from its 52-week high?
BioCryst Pharmaceuticals Inc trades at $7.69, about 31% below its 52-week high of $11.11 and 23% above the low of $6.24 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $17.01 is for.
Which stocks are comparable to BioCryst Pharmaceuticals Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is BioCryst Pharmaceuticals Inc stock attractive at the current price?
The data as of Nov 7, 2026: price $7.69, calculated fair value $17.01 (+121%), Quality Score 72/100, from 21 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BCRX calculated?
We run BioCryst Pharmaceuticals Inc through 21 models from 6 families: DCF Models, Earnings-Based, Multiples, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $17.01 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. BioCryst Pharmaceuticals Inc currently trades 55% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of BioCryst Pharmaceuticals Inc (BCRX)?
The closing price on Nov 6, 2026 was $7.69. Our model-based fair value is $17.01, about +121% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with BioCryst Pharmaceuticals Inc right now?
The price is below even our cautious bear case ($11.26). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (72/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range ($11.26 to $22.12) leaves room in how you read the outcome.

Key figures of BioCryst Pharmaceuticals Inc

How large is the market capitalisation of BioCryst Pharmaceuticals Inc (BCRX)?
The market capitalisation of BioCryst Pharmaceuticals Inc is $2.0B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of BioCryst Pharmaceuticals Inc (BCRX)?
The price-to-sales ratio of BioCryst Pharmaceuticals Inc is 2.04 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of BioCryst Pharmaceuticals Inc (BCRX)?
Earnings per share at BioCryst Pharmaceuticals Inc are $−1.28. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of BioCryst Pharmaceuticals Inc (BCRX)?
The net margin of BioCryst Pharmaceuticals Inc is −37.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of BioCryst Pharmaceuticals Inc (BCRX)?
The return on equity (ROE) of BioCryst Pharmaceuticals Inc is −1,925% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of BioCryst Pharmaceuticals Inc (BCRX)?
On an EBIT basis the return on assets of BioCryst Pharmaceuticals Inc is −2.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of BioCryst Pharmaceuticals Inc (BCRX)?
The operating margin of BioCryst Pharmaceuticals Inc is 29.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at BioCryst Pharmaceuticals Inc (BCRX)?
Revenue at BioCryst Pharmaceuticals Inc is growing +13.1% versus a year earlier (3y avg +47.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at BioCryst Pharmaceuticals Inc (BCRX)?
Earnings per share at BioCryst Pharmaceuticals Inc are growing +133% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does BioCryst Pharmaceuticals Inc (BCRX) carry?
The net debt of BioCryst Pharmaceuticals Inc is $388M (fiscal year 2025, ≈ 1.2 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch BioCryst Pharmaceuticals Inc in the live analysis

One click puts BioCryst Pharmaceuticals Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.